DZD Announces High-Caliber Additions to Leadership Team and Advisory Board
November 17 2020
Dekel Gelbman joins as SVP, Business Development & Strategy, Robin Patel, M.D. joins DZD's clinical and scientific advisory board and Sally Hojvat, Ph.D. joins as a regulatory strategy advisor
Read More
Day Zero Diagnostics Moves Headquarters to SmartLabs at Boston Landing
August 3 2020
Company now occupies over 9,000 square feet of cutting-edge office and lab space
Read More
DZD Announces Positive Data from Multiple Studies Demonstrating Promise of New Technology
October 21 2020
Initial results show new class of diagnostics can provide culture-free pathogen identification and drug-resistance profile within hours, not days
Read More
DZD Research Highlighted in Two Publications on Plasmid-Mediated Antibiotic Resistance
June 2 2020
DZD technical expertise enables identification of novel mechanisms of antibiotic resistance using nanopore sequencing
Read More
DZD Awarded $6.2M Non-Dilutive Funding to Develop Rapid Antibiotic Resistance Diagnostic
May 11 2020
CARB-X selects Day Zero Diagnostics for their global portfolio of technologies to combat antibiotic-resistance
Read More
EpiXact® Helps Stop a Carbapenem-Resistant Acinetobacter baumannii Outbreak in a Burn ICU
February 28 2020
Research published in Infection Control and Hospital Epidemiology details use of patient and environmental whole genome sequencing to stop a CRAB outbreak
Read More